Assenagon Asset Management S.A. raised its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 105.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,023,507 shares of the company’s stock after acquiring an additional 524,797 shares during the quarter. Assenagon Asset Management […]
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) CAO James George Chopas sold 1,061 shares of the business’s stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $65.00, for a total transaction of $68,965.00. Following the completion of the sale, the chief accounting officer now directly owns […]
Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) gapped down before the market opened on Tuesday following insider selling activity. The stock had previously closed at $65.45, but opened at $63.81. Apellis Pharmaceuticals shares last traded at $63.90, with a volume of 195,943 shares changing hands. Specifically, CAO James George Chopas sold 864 […]
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report)’s share price gapped down prior to trading on Tuesday after an insider sold shares in the company. The stock had previously closed at $65.45, but opened at $63.81. Apellis Pharmaceuticals shares last traded at $63.90, with a volume of 195,943 shares changing hands. Specifically, insider Jeffrey Eisele […]
Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price target hoisted by HC Wainwright from $82.00 to $92.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm currently has a buy rating on the stock. APLS has been the subject of a number of other reports. Wells Fargo & Company downgraded […]